Woodline Partners’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Woodline Partners’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-143,980	Closed	-$1.28M	–	796
2023 Q1	$1.28M	Sell	143,980 -90,022	-38%	-$884K	0.02%	459
2022 Q4	$1.17M	Sell	234,002 -2,388	-1%	-$14K	0.02%	533
2022 Q3	$1.37M	Buy	236,390 +24,706	+12%	+$175K	0.02%	508
2022 Q2	$1.17M	Sell	211,684 -38,316	-15%	-$316K	0.02%	500
2022 Q1	$2.88M	Hold	250,000	–	–	0.05%	330
2021 Q4	$3.17M	Buy	+250,000	New	+$3.77M	0.05%	349

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Woodline Partners's THRX Position: Q2 2023 in Review

Woodline Partners sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2023, closing a stake of 143,980 shares — an estimated $1.28M sold.

Woodline Partners first reported a position in THRX in Q4 2021 and held it in 6 quarters. The position peaked at $3.17M in Q4 2021. 69 funds tracked by Wall St. Rank hold THRX as of Q2 2023.

Woodline Partners reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Woodline Partners sold 143,980 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $1.28M.
Woodline Partners first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Woodline Partners's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $3.17M in Q4 2021.
69 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.